Time Course of Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone
Open Access
- 30 September 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (2) , 206-216
Abstract
The increase in opioid overdose deaths, particularly involving potent, long‐acting synthetic opioids, has led to calls for stronger, longer‐acting opioid‐overdose‐reversal agents. Using an opioid‐induced respiratory depression model, we investigated the onset and time course of action of naloxone and a long‐acting opioid antagonist, nalmefene, in reversing the effects of an ongoing intravenous fentanyl infusion over a period of up to 100 min. Healthy, moderately experienced opioid users received intramuscular (IM) nalmefene 1 mg, IM naloxone 2 mg, or intranasal (IN) naloxone 4 mg after fentanyl‐induced respiratory depression was established based on reduction in respiratory minute volume (MV). Each participant received each opioid antagonist twice per a randomized crossover schedule. Reversal of respiratory depression, pharmacokinetics, and safety were investigated. Participants showed rapid increases in plasma opioid antagonist concentrations, and meaningful reversal of depressed MV tended to occur earlier with IM nalmefene and IM naloxone than with IN naloxone. Compared to naloxone, nalmefene provided extended exposure, and mean MV was maintained at a higher level. All participants experienced treatment‐related adverse events, but none were severe, serious, or led to study drug discontinuation. This study provides evidence that IM nalmefene 1 mg achieves reversal of fentanyl‐induced respiratory depression similar to or better than that achieved with standard‐of‐care naloxone treatments. No new safety concerns were raised for IM nalmefene at the tested dose. The pharmacokinetic and pharmacodynamic properties of IM nalmefene position it as an important treatment option in opioid overdose reversal, particularly given the increasing prevalence of overdoses involving potent, long‐acting synthetic opioids.Keywords
This publication has 30 references indexed in Scilit:
- Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal NaloxoneThe Journal of Clinical Pharmacology, 2024
- The epidemic of fentanyl misuse and overdoses: challenges and strategiesWorld Psychiatry, 2021
- Continued Increases in Overdose Deaths Related to Synthetic OpioidsJAMA, 2021
- FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific EngagementClinical Pharmacology & Therapeutics, 2020
- Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve IndividualsClinical Pharmacology & Therapeutics, 2020
- Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive reviewNeuropharmacology, 2018
- The Role of Science in Addressing the Opioid CrisisNew England Journal of Medicine, 2017
- [3H]Alvimopan binding to the μ opioid receptor: Comparative binding kinetics of opioid antagonistsEuropean Journal of Pharmacology, 2005
- Double-Blind, Randomized Study of Nalmefene and Naloxone in Emergency Department Patients With Suspected Narcotic OverdoseAnnals of Emergency Medicine, 1999
- Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: A pilot studyAnnals of Emergency Medicine, 1993